stay updated

Explore the latest news from Khondrion and its team.

events

 

No event found!

news

Reflections on SSIEM annual symposium 2019 – Building Bridges

Reflections on SSIEM annual symposium 2019 – Building Bridges   Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM): Having returned from this year’s...

New Year brings new look at khondrion.com

Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the launch of its new website.As the company continues to advance its proprietary science through a wholly-owned clinical and...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the Netherlands – November 2018: Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies...

Jan Smeitink interview with Catalyze

In July 2018 Khondrion was awarded €2.3M funding from the EU Horizon 2020 Research and Innovation programme to progress clinical development of KH176, its lead pipeline asset. Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, talks to Catalyze®, who collaborated with Khondrion on the company’s successful funding submission, about his ambitions for Khondrion and the mitochondrial disease research his team is leading.

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.

KH176 published in Scientific Reports

Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases.

Khondrion will present first results of KHENERGY study

Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.

New Patents granted for KH176

New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the grant of key patents in...

KHENERGY: completion of recruitment and first-in-patient dosing

Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical trial with KH176 in MELAS/MIDD and mixed mitochondrial syndromes NIJMEGEN, The Netherlands – Khondrion, a clinical-stage...

EFRO Grant to support the KHENERGYC study

THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial disease NIJMEGEN, the Netherlands – Khondrion, the clinical-stage pharmaceutical company focusing on small molecule...

KH176 Phase 2 clinical trial

Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes NIJMEGEN, The Netherlands – Khondrion, the clinical-stage pharmaceutical company focusing on small molecule therapeutics...

Khondrion partner in REMIX EU research project

Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU research initiative REMIX aims to combine the skills of European research groups to provide strategic training of the next...

KH176 Phase 1 Clinical trials

December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the...

Khondrion partner in SysMedPD EU research project

Press Release New EU research project SysMedPD joins forces between universities’ research facilities and Khondrion New EU research initiative aims to develop drugs to slow down the progression of Parkinson’s disease Nijmegen, 01 December 2015...

EMA Orphan Drug Designation

EMA Orphan Drug Designation Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound KH176, in the treatment of Leigh syndrome (EU/3/14/1336)

Interview PharmaBoardroom

Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases,...

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that Hans...

EMA Orphan Drug Designation for MELAS syndrome

Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that the European Commission has granted Khondrion...

Clinical Trial Phase 1

NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the initiation of a Phase 1 Clinical Trial with its frontrunner compound KH176. The Trial will be a...

New CMO joins Khondrion

Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion's Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion, The Netherlands based biopharmaceutical company developing a treatment for mitochondrial disease, announced today the...

FDA Orphan Drug Designation

Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of inherited mitochondrial respiratory chain diseases.